Ponaxen 45mg Tablet (Ponatinib)

Ponaxen 45mg Tablet is a target therapy-based allopathic medication which is used to treat various phases of Chronic Myeloid Leukemia (CML) as well as Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL). It has an active ingredient known as ponatinib that belongs to the class of medications called tyrosine kinase inhibitors. Ponatinib 45mg Tablet (Ponaxen) blocks the abnormal BCR-ABL protein, including forms with the T315I mutation, as it is responsible for cancer cell growth and proliferation. Thus, this binds to the mutated BCR-ABL tyrosine kinase that inhibits further signaling of cancer progression. As a result, the cancer cell eventually dies.

The tablet is taken orally and exactly as prescribed by the doctor. The tablet must be swallowed as whole with water and should not be crushed, chewed, or broken. It is usually taken with or without food. A Ponatinib 45mg Tablet is given once daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of cancer. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include skin rash, dry skin, abdominal pain, constipation, diarrhea, nausea, headache, tiredness, joint or muscle pain, and changes in blood counts. A few patients can undergo severe side effects, including heart attack, stroke, severe hypertension, liver toxicity, pancreatitis and heart failure. Most of the Ponatinib 45mg Tablet side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The medicine can cause fetal harm and should not be used during pregnancy. Women who can become pregnant should use effective contraception during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Ponatinib 45mg Tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Adult patients with specific advanced blood cancers, notably Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), particularly for cases that are resistant to prior treatments or carry the T315I mutation.

Ponatinib 45mg Tablet is an allopathic medicine that requires a prescription for purchase. This is a part of a targeted therapeutic drug. Its chemical-based formula leads to multiple side effects like any other chemical-based medication. Visit your doctor if these side effects remain for a longer period of time.

Common side effects of the Ponatinib 45mg tablet are:
● Fever
● Constipation
● Rashes
● Weight Loss
● Abdominal Pain
● Anemia
● Pneumonia
● Pancreatitis
● Myocardial Infarction
● Hypertension
● Cardiac Failure
● Acute Kidney Injury
● Febrile Neutropenia

Ponatinib 45mg Tablet is taken orally once a day with or without food. This is the usual starting dosage for adults but can vary later based on the cancer stage and its progression. Tablets should be consumed whole as they are without breaking, chewing or biting to maintain their efficacy. For exact dosage, contact your doctor. Don't miss the dosage and remain consistent about medication.

● Jain, H., Thorat, J., Sengar, M., & Dubey, A. (2019). Ponatinib: A drug review. Cancer Research, Statistics, and Treatment, 2(2), 190-196.
● Attwa, M. W., Alkahtani, H. M., El-Azab, A. S., Abdel-Aziz, A. A. M., Abdelhameed, A. S., Kadi, A. A., ... & Bakheit, A. H. (2024). ● Ponatinib: A comprehensive drug profile. Profiles of Drug Substances, Excipients and Related Methodology, 49, 81-114.
● Shamroe, C. L., & Comeau, J. M. (2013). Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. Annals of Pharmacotherapy, 47(11), 1540-1546.
● Narasimhan, N. I., Dorer, D. J., Niland, K., Haluska, F., & Sonnichsen, D. (2013). Effects of food on the pharmacokinetics of ponatinib in healthy subjects. Journal of clinical pharmacy and therapeutics, 38(6), 440-444.